NIKKEI 225
37,628.48 -831.60 (-2.16%) HANG SENG
17,284.54 +83.27 (+0.48%) CRUDE OIL
83.61 +0.80 (+0.97%) GOLD FUTURES
2,345.50 +7.10 (+0.30%) DOW
37,983.14 -477.78 (-1.24%) Bitcoin GBP
51,597.90 +314.31 (+0.61%)
Amedisys, Inc. (AMED)
| Previous close | 91.05 |
| Open | 90.90 |
| Bid | 90.84 x 100 |
| Ask | 91.15 x 100 |
| Day's range | 90.33 - 91.27 |
| 52-week range | 73.10 - 96.44 |
| Volume | |
| Avg. volume | 279,574 |
| Market cap | 2.973B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Amedisys Reports First Quarter 2024 Financial Results
BATON ROUGE, La., April 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2024. Three-Month Periods Ended March 31, 2024 and 2023 Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023. Prior year included $15.0 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of $14.4 millio
- GlobeNewswire
Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results
BATON ROUGE, La., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was divested on March 31, 2023.Net income attributable to Amedisys, Inc. of
- GlobeNewswire
Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis
BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve t
